You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Find more safety information in the supplementary patient handout How to Safely Take Your Oral Anti-Cancer Medication.

Displaying Drugs List

13 Items
Other Name(s): Nolvadex®-D (multiple brands available)
Funding:
ODB - General Benefit
  • tamoxifen
Jun 2017
Other Name(s): Temodal®
Funding:
ODB Limited Use
  • temozolomide - Newly diagnosed glioblastoma multiforme (concurrent radiotherapy then maintenance)
  • temozolomide - Recurrent or progressive glioblastoma multiforme or anaplastic astrocytoma
Sep 2019
Other Name(s): Torisel ® (Pfizer)
Funding:
New Drug Funding Program
  • Temsirolimus - Metastatic Renal Cell Carcinoma
Apr 2017
Other Name(s): Vumon® (Bristol-Myers Squibb)
Apr 2016
Other Name(s): Thalomid®
Funding:
Exceptional Access Program
  • thalidomide - Multiple myeloma in patients ≥65 years of age in combination with melphalan and prednisone, with specific criteria
Jun 2019
Other Name(s): Lanvis®
Funding:
ODB - General Benefit
  • thioguanine
Jun 2019
Other Name(s): Hycamtin® (multiple brands available)
Funding:
New Drug Funding Program
  • Topotecan - Single Agent Treatment of Platinum Sensitive Ovarian Fallopian Tube or Primary Peritoneal Cancer
  • Topotecan - Platinum-Resistant Ovarian Fallopian Tube or Primary Peritoneal Cancer
May 2018
Other Name(s): Yondelis® (Janssen)
Aug 2018
Other Name(s): Mekinist®
Funding:
Exceptional Access Program
  • trametinib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable or metastatic melanoma, according to specific criteria
  • trametinib - In combination with dabrafenib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma, according to specific clinical criteria
  • trametinib - For the adjuvant treatment of resected Stage III cutaneous melanoma according to clinical criteria
Jan 2020
Other Name(s): Herceptin®, Ogivri™, Trazimera™, Herzuma®
Funding:
Evidence Building Program
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer Supplemental
  • Trastuzumab (EBP) - Adjuvant Treatment for Breast Cancer
New Drug Funding Program
  • Trastuzumab (Biosimilar) with First Line Docetaxel - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Vinorelbine - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Docetaxel - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Single Agent - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Second Line - Metastatic Breast Cancer
  • Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
  • Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
  • Trastuzumab (Biosimilar) in combination with Paclitaxel - Metastatic Breast Cancer
Updated
Feb 2020
Other Name(s): Vesanoid®
Funding:
Exceptional Access Program
  • tretinoin (ATRA)
Jun 2019
Other Name(s): Lonsurf®
Jun 2019